Phase 1 studies are the springboard for advancing new cancer treatments. Through phase 1 studies, the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer patients first-in-human clinical trials of immunotherapies and other novel cancer therapies, including these two recently opened studies:
A Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
This phase 1/2 first-in-human study will evaluate RP1 alone and in combination with nivolumab in adults with advanced and/or refractory solid tumors. RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and to generate an anti-tumor immune response. Nivolumab is a PD1 blockade that helps the immune system kill cancer cells. Providence is one of only two sites in the U.S. currently offering this study.
This is a phase 1/2 first-in-human study of A166 in patients with HER2-expressing or amplified solid tumors who have exhausted available standard therapies. A166 is an antibody drug conjugate that targets HER2-expressing cancer cells.
For more information or to enroll a patient, please call our Clinical Research office at 503-215-2614.
See more studies
Providence Cancer Institute currently offers more than 100 phase 1, 2 and 3 clinical trials. New studies are added frequently. To see all current studies, please visit our website.
An exceptional team
The phase 1 research program at the Earle A. Chiles Research Institute at Providence Cancer Institute is made up of oncology leaders, phase-1-dedicated nurses, data coordinators and lab assistants. Every person on this exceptional team is passionate about offering breakthrough therapies and the best possible treatment for our patients.
About the Author
More Content by Providence News Team
